GH administration decreases subcutaneous abdominal adipocyte size in men with abdominal obesity.
Growth Horm IGF Res
; 35: 17-20, 2017 08.
Article
in En
| MEDLINE
| ID: mdl-28628810
ABSTRACT
OBJECTIVE:
To investigate the effects of short-term GH administration on abdominal subcutaneous adipocyte size and CT attenuation in men with abdominal obesity.DESIGN:
6-week, randomized, double-blind, placebo-controlled study of GH (starting dose 2µg/kg/d) vs placebo of 15 abdominally obese men (mean age 34±6years; mean BMI 37.7±6.1kg/m2, mean IGF-1 SDS -1.9±0.5) who underwent abdominal subcutaneous adipose tissue (SAT) aspirations to determine adipocyte size, CTs for body composition and measures of glucose tolerance at baseline and 6weeks. GH dosing was titrated to target IGF-1 levels in the upper normal age-appropriate range.RESULTS:
GH administration decreased subcutaneous abdominal adipocyte size compared to placebo. Adipocyte size was positively associated with 120-min glucose and HOMA-IR and inversely associated with peak-stimulated GH and CT attenuation. CT attenuation of SAT was inversely associated with 120-min glucose and HOMA-IR and increased following GH administration.CONCLUSION:
In men with abdominal obesity, subcutaneous abdominal adipocyte size is positively associated with measures of impaired glucose tolerance and administration of GH at doses that raise IGF-1 levels within the normal range, decreases abdominal subcutaneous adipocyte size, suggesting that GH administration improves the health of adipose tissue. Clinical trials number NCT00131378.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Adipocytes
/
Human Growth Hormone
/
Subcutaneous Fat, Abdominal
/
Obesity, Abdominal
Type of study:
Clinical_trials
Limits:
Adult
/
Humans
/
Male
Language:
En
Journal:
Growth Horm IGF Res
Journal subject:
ENDOCRINOLOGIA
Year:
2017
Document type:
Article